Pluri Inc. (NASDAQ:PLUR) Sees Large Decline in Short Interest

Pluri Inc. (NASDAQ:PLUR) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 2,300 shares, a decline of 62.3% from the September 30th total of 6,100 shares. Based on an average daily trading volume, of 11,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the company’s stock are sold short.

Pluri Stock Down 4.0 %

PLUR stock opened at $4.32 on Friday. The company has a fifty day moving average price of $5.25 and a 200 day moving average price of $5.50. Pluri has a 12 month low of $3.45 and a 12 month high of $8.48. The company has a market cap of $23.63 million, a price-to-earnings ratio of -0.73 and a beta of 1.60. The company has a debt-to-equity ratio of 4.44, a current ratio of 6.98 and a quick ratio of 6.98.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Wednesday, September 18th. The company reported ($2.98) EPS for the quarter. The firm had revenue of $0.26 million for the quarter. Pluri had a negative return on equity of 493.74% and a negative net margin of 6,341.03%.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.